Show simple item record

dc.contributor.authorSaesen, R.
dc.contributor.authorVan Hemelrijck, M.
dc.contributor.authorBogaerts, J.
dc.contributor.authorBooth, C. M.
dc.contributor.authorCornelissen, J. J.
dc.contributor.authorDekker, A.
dc.contributor.authorEisenhauer, E. A.
dc.contributor.authorFreitas, Andre
dc.contributor.authorGronchi, A.
dc.contributor.authorHernán, M. A.
dc.contributor.authorHulstaert, F.
dc.contributor.authorOst, P.
dc.contributor.authorSzturz, P.
dc.contributor.authorVerkooijen, H. M.
dc.contributor.authorWeller, M.
dc.contributor.authorWilson, R.
dc.contributor.authorLacombe, D.
dc.contributor.authorvan der Graaf, W. T.
dc.date.accessioned2023-05-17T09:50:41Z
dc.date.available2023-05-17T09:50:41Z
dc.date.issued2023en
dc.identifier.citationSaesen R, Van Hemelrijck M, Bogaerts J, Booth CM, Cornelissen JJ, Dekker A, et al. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer. European journal of cancer (Oxford, England : 1990). 2023 Mar 21;186:52-61. PubMed PMID: 37030077. Epub 2023/04/09. eng.en
dc.identifier.pmid37030077en
dc.identifier.doi10.1016/j.ejca.2023.03.013en
dc.identifier.urihttp://hdl.handle.net/10541/626219
dc.description.abstractThe emergence of the precision medicine paradigm in oncology has led to increasing interest in the integration of real-world data (RWD) into cancer clinical research. As sources of real-world evidence (RWE), such data could potentially help address the uncertainties that surround the adoption of novel anticancer therapies into the clinic following their investigation in clinical trials. At present, RWE-generating studies which investigate antitumour interventions seem to primarily focus on collecting and analysing observational RWD, typically forgoing the use of randomisation despite its methodological benefits. This is appropriate in situations where randomised controlled trials (RCTs) are not feasible and non-randomised RWD analyses can offer valuable insights. Nevertheless, depending on how they are designed, RCTs have the potential to produce strong and actionable RWE themselves. The choice of which methodology to employ for RWD studies should be guided by the nature of the research question they are intended to answer. Here, we attempt to define some of the questions that do not necessarily require the conduct of RCTs. Moreover, we outline the strategy of the European Organisation for Research and Treatment of Cancer (EORTC) to contribute to the generation of robust and high-quality RWE by prioritising the execution of pragmatic trials and studies set up according to the trials-within-cohorts approach. If treatment allocation cannot be left up to random chance due to practical or ethical concerns, the EORTC will consider undertaking observational RWD research based on the target trial principle. New EORTC-sponsored RCTs may also feature concurrent prospective cohorts composed of off-trial patients.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ejca.2023.03.013en
dc.titleDefining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Canceren
dc.typeArticleen
dc.contributor.departmentEuropean Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgiumen
dc.identifier.journalEuropean Journal of Canceren
dc.description.noteen]
refterms.dateFOA2023-05-17T10:32:34Z


Files in this item

Thumbnail
Name:
37030077.pdf
Size:
1.198Mb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record